Iceland· IS-EU/1/19/1399/001
Xospata
A gilteritinib product containing gilteritinibum inn,gilteritinibum inn fúmarat, registered in Iceland by Astellas Pharma Europe B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Gilteritinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX13 (gilteritinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Gilteritinib · ATC L01EX13
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of gilteritinib costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Gilteritinib · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- CH Switzerland$662.17
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Gilteritinibum INN,Gilteritinibum INN fúmarat
- Manufacturer
- Astellas Pharma Europe B.V.
- Country
- Iceland (IS)
- ATC code
- L01EX13
- ATC class
- Gilteritinib
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean99761184 stk x1 þpakkiISK 3218966
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
529 interactions on record for gilteritinib.
Graded by severity as the source publishes them — 116 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gilteritinib · interactions on record
529 records
- 116 severe
- 408 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EX13
Gilteritinib, as other registers publish it.
- United KingdomGilteritinib 40mg tabletsAstellas Pharma Ltd
- FinlandXospataAstellas Pharma Europe B.V.
- DenmarkXospataAstellas Pharma Europe B.V.
- NorwayXospataAstellas Pharma Europe B.V. - Leiden
- United StatesXospataAstellas Pharma US, Inc.
- PolandXospataAstellas Pharma Europe B.V.
- United StatesXospataAstellas Pharma US, Inc.
- CanadaXOSPATAASTELLAS PHARMA CANADA INC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/141639d0-1bb2-4453-aa27-a461254778a5 GET /v1/drugs/141639d0-1bb2-4453-aa27-a461254778a5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01EX13",
"marketed": false,
"strength": "40 mg",
"ma_number": "EU/1/19/1399/001",
"substance": "Gilteritinibum INN,Gilteritinibum INN fúmarat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum og krabbameinslækningum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43762"
}See everything about gilteritinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.